Of note, PIM inhibition sensitized both MYCN-amplified and wild-type, ALK-driven neuroblastoma cells to ALK inhibitors both in vitro and in vivo, suggesting co-inhibition of PIM and ALK as a viable strategy to enhance the efficacy of ALK inhibitors. The gene discussed is MYCN; the disease is neuroblastoma.